Lin Xia, Tang Xiaoyan, Su Feng, Shi Tingting, Zeng Di, Liu Shiping
General Practice, Affiliated Hospital of North Sichuan Medical College Nanchong 637000, Sichuan, China.
Am J Transl Res. 2024 Dec 15;16(12):7757-7764. doi: 10.62347/SSTO6670. eCollection 2024.
To evaluate the efficacy of double filtration plasmapheresis combined with immunosuppressive agents in the treatment of severe lupus nephritis.
A retrospective analysis was conducted on the medical records of 102 cases of severe lupus nephritis treated between January 2021 and December 2022 in the General Practice Department at the Affiliated Hospital of North Sichuan Medical College. Patients who received immunosuppressive agents were included in the control group and those who received additional double filtration plasmapheresis were included in the observation group. Changes in liver and kidney function indicators, immune function indicators, disease activity, peripheral blood immunoglobulins, total albumin levels, gamma globulin levels, erythrocyte sedimentation rates (ESR), and inflammatory marker levels, and overall clinical efficacy were compared between the two groups.
After therapy, kidney function indicators in the observation group were lower than in the control group, while serum albumin (Alb), total albumin level, complement component 3 (C3) and C4 levels were higher (all P<0.05). Anti-double-stranded DNA antibody (ds-DNA) and white blood cell (WBC) counts in the observation group were also lower than those in the control group. Additionally, the systemic lupus erythematosus disease activity index (SLEDAI) scores, the levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), and ESR were lower in the observation group than those in the control group (all P<0.05). The total clinical effective rate was higher in the observation group than in the control group (P<0.05).
The combination of immunosuppressive agents with double filtration plasmapheresis in patients with severe lupus nephritis can significantly improve liver and kidney function, enhance immune function, and reduce inflammation, demonstrating good therapeutic effects and safety.
评估双重过滤血浆置换联合免疫抑制剂治疗重症狼疮性肾炎的疗效。
对2021年1月至2022年12月在川北医学院附属医院全科医学科治疗的102例重症狼疮性肾炎患者的病历进行回顾性分析。接受免疫抑制剂治疗的患者纳入对照组,接受额外双重过滤血浆置换的患者纳入观察组。比较两组患者的肝肾功能指标、免疫功能指标、疾病活动度、外周血免疫球蛋白、总白蛋白水平、γ球蛋白水平、红细胞沉降率(ESR)和炎症标志物水平以及总体临床疗效。
治疗后,观察组的肾功能指标低于对照组,而血清白蛋白(Alb)、总白蛋白水平、补体成分3(C3)和C4水平更高(均P<0.05)。观察组的抗双链DNA抗体(ds-DNA)和白细胞(WBC)计数也低于对照组。此外,观察组的系统性红斑狼疮疾病活动指数(SLEDAI)评分、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)水平和ESR均低于对照组(均P<0.05)。观察组的总临床有效率高于对照组(P<0.05)。
重症狼疮性肾炎患者采用免疫抑制剂联合双重过滤血浆置换可显著改善肝肾功能,增强免疫功能,减轻炎症,显示出良好的治疗效果和安全性。